GILD Stock Lost 4%, Gilead Sciences Disputes Report on Poor Results of Remdesivir Trial

Posted on April 24, 2020
In Business, coronavirus, coronavirus crisis, coronavirus vaccine, COVID-19, covid-19 vaccine, Editor's Choice, gild stock, gild stock price, gilead sciences, gilead sciences remdesivir, gilead sciences stock, gilead sciences stock price, Market News, News, remdesivir, Stocks, wall street

Coinspeaker
GILD Stock Lost 4%, Gilead Sciences Disputes Report on Poor Results of Remdesivir Trial

WHO accidentally posted a draft summary of remdesivir trial studies. As soon as the organization realized the mistake, it deleted the post. But Gilead (GILD) stock plunged.

Coinspeaker

39 total views, 1 views today

Author: toutiao

Please Enter a Comment

Load more (0)